<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17824">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874846</url>
  </required_header>
  <id_info>
    <org_study_id>AR-13324-CS204</org_study_id>
    <nct_id>NCT02874846</nct_id>
  </id_info>
  <brief_title>Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal
      Intraocular Pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intraocular pressure over 24-hour period (measured at 10 pm, midnight, 3 am and 6 am)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Netarsudil Ophthalmic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ophthalmic solution once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ophthalmic solution (placebo) once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil ophthalmic solution</intervention_name>
    <description>Ophthalmic solution once daily</description>
    <arm_group_label>Netarsudil Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Ophthalmic solution (placebo) once daily</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older.

          2. Ocular hypertension or open-angle glaucoma in both eyes.

          3. Unmedicated intraocular pressure &gt; 17 mmHg in one or both eyes and &lt; 30 mmHg in both
             eyes.

          4. Corrected visual acuity in each eye equivalent to 20/200 or better.

          5. Able and willing to give signed informed consent and follow study instructions.

        Exclusion Criteria:

          1. Glaucoma with pseudoexfoliation or pigment dispersion component, history of angle
             closure, narrow angles.

          2. Intraocular pressure ≥ 30 mmHg.

          3. Use of ocular medications within 30 days.

          4. Known hypersensitivity to any component of the test formulations or to medications
             used routinely during a clinical eye examination.

          5. Previous eye surgery (other than cataract).

          6. Ocular trauma within 6 months.

          7. Clinically significant ocular disease that might interfere with the study.

          8. Central corneal thickness greater than 620 µm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Ramirez</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nancy Ramirez</name>
      <address>
        <city>Bedminster</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 12, 2016</lastchanged_date>
  <firstreceived_date>August 15, 2016</firstreceived_date>
  <firstreceived_results_disposition_date>September 27, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
